AACR Journals

Welcome to the official LinkedIn page for the AACR Journals! Connect with our community to keep up to date with AACR Journals’ content, researchers, events, and opportunities.

Featured article in Cancer Immunology Research: Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells Hypersialylation of tumors can result in immune escape and tumor growth. Using CRISPR to knock out the inhibitory receptor Siglec-9, as well as through studies with Siglec-9-based chimeric switch receptors (CSR) in a human tumor xenograft model, Eisenberg and colleagues showed that human T cells also experience Siglec-9/sialic acid signaling, which hinders anti-tumoral effector function. Go deeper: https://bit.ly/3YidH0q

Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations: https://bit.ly/48ltrnW

Cancer Research Communications, American Association for Cancer Research's open access, peer-reviewed journal that spans the full breadth of cancer science and medicine, supports authors throughout the peer review process from pre-submission through publication. Learn more: https://bit.ly/3NFfvMc

Read the article by Salma Kaochar, PhD, MFA, recipient of the 2024 Cancer Research Early Career Award: https://bit.ly/4hh8HSt This award recognizes outstanding early career investigators who have authored peer-reviewed, original articles published in Cancer Research that have made a significant impact in one or more of the fields represented by the Journal. Baylor College of Medicine

Headed to today's "Novel frontiers for the immunotherapy of cancer" session at #ENASymp24? Check out the recent #FirstDisclosure of the novel B7-H3-targeted CD28 bispecific antibody XmAb808, published in Molecular Cancer Therapeutics: https://lnkd.in/eYcrrtkm #openaccess

In a large comparative oncology study, cancer prevalence varied widely across different vertebrates, with prevalence generally decreasing with gestation time and increasing with body mass. The results of the study were published in the @AACR Journals Cancer Discovery. Learn more: https://bit.ly/3YjlcnN

Every now and then an opportunity comes along to publish a review article at exactly the right time by exactly the right authors - I'm very excited to share one such review article published online in Cancer Discovery today for the start of #ENASymp24: The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development, by Raffaele Colombo, Paolo Tarantino, Jamie Rich, Patricia LoRusso, and Elisabeth (Liesbeth) de Vries In this article, thought leaders in the field provide an overview of the past 4 decades of development of this drug class; discuss issues related to ADC toxicity, efficacy, stability, distribution, and disposition in normal tissues; and provide their perspective on challenges related to clinical optimization, sequencing strategies, and predictive biomarkers. AACR Journals

Attending #ENASymp24? Don't miss Towards Degrader-Antibody Conjugates, a new journal article collection from the American Association for Cancer Research that includes research and review articles on the preclinical to early clinical development of novel ADCs and protein degraders. Read the articles: https://bit.ly/3YhJhLQ

Headed to today's #ENASymp24 session on fine-tuning the use of #ADCs? Don't miss the #FirstDisclosure of novel ADC ZD06519, published in Molecular Cancer Therapeutics, by speaker Raffaele Colombo: https://lnkd.in/efXks5Wk Zymeworks Inc. #openaccess